Fresenius Medical Care AG & Co. KGaA (FME) Given a €68.00 Price Target by Jefferies Financial Group Analysts

Jefferies Financial Group set a €68.00 ($79.07) price objective on Fresenius Medical Care AG & Co. KGaA (ETR:FME) in a report released on Thursday morning, Borsen Zeitung reports. The brokerage currently has a neutral rating on the stock.

FME has been the subject of several other research reports. HSBC set a €87.00 ($101.16) price objective on shares of Fresenius Medical Care AG & Co. KGaA and gave the stock a buy rating in a report on Wednesday, February 13th. JPMorgan Chase & Co. set a €86.50 ($100.58) price objective on shares of Fresenius Medical Care AG & Co. KGaA and gave the stock a buy rating in a report on Tuesday, April 30th. Berenberg Bank set a €88.65 ($103.08) price objective on shares of Fresenius Medical Care AG & Co. KGaA and gave the stock a buy rating in a report on Tuesday, March 5th. Goldman Sachs Group set a €79.00 ($91.86) price objective on shares of Fresenius Medical Care AG & Co. KGaA and gave the stock a buy rating in a report on Monday, April 1st. Finally, Deutsche Bank set a €100.00 ($116.28) price objective on shares of Fresenius Medical Care AG & Co. KGaA and gave the stock a buy rating in a report on Friday, April 26th. Eight analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The company presently has an average rating of Buy and a consensus target price of €83.90 ($97.56).

FME stock opened at €76.32 ($88.74) on Thursday. The stock has a market capitalization of $23.19 billion and a P/E ratio of 11.83. Fresenius Medical Care AG & Co. KGaA has a fifty-two week low of €55.44 ($64.47) and a fifty-two week high of €91.74 ($106.67). The company has a debt-to-equity ratio of 58.49, a current ratio of 1.25 and a quick ratio of 0.96.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

See Also: What is channel trading?

Analyst Recommendations for Fresenius Medical Care AG & Co. KGaA (ETR:FME)

Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.